Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP15 | Q460N3 | 3/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 6/20 | 0.41 |
| ▸ | MAOA | P21397 | 5/20 | 0.41 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.36 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.35 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.35 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.34 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6846696 | 0.67 | MAOB (0.58) | MAOBMAOA | |
| SCHEMBL18340255 | 0.64 | SIRT2 (0.59) | SIRT2SIRT1SIRT3 | |
| SCHEMBL7449022 | 0.64 | SIRT2 (0.51) | PARP15PARP10MAOBSIRT2NR1H2 | |
| SCHEMBL18428626 | 0.63 | GRM2 (0.61) | — | |
| SCHEMBL203978 | 0.63 | MAOB (0.55) | PARP10MAOBSIRT2SIRT1SIRT3 | |
| SCHEMBL21808795 | 0.63 | MAOB (0.42) | PARP15PARP10MAOBPARP14CYP11B2 | |
| SCHEMBL24933394 | 0.62 | PARP15 (0.39) | PARP15PARP10MAOBPARP14CYP11B2 | |
| SCHEMBL30240728 | 0.62 | PARP15 (0.39) | PARP15PARP10MAOBPARP14CYP11B2 | |
| SCHEMBL18347100 | 0.62 | SIRT2 (0.62) | MAOBMAOASIRT2SIRT1SIRT3 | |
| SCHEMBL18339411 | 0.61 | MAOB (0.52) | MAOBSIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BENDER STEVEN LEE (US) | 2004-05-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | PARP15 1506/4885PARP10 1306/4885MAOB 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.